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Synchronized coronary venous retroperfusion was used during 
coronary balloon angioplasty to support the ischemic myocardium 
of 20 patients with unstable angina and anatomy at high risk of a 
coronary event. Hemodynamics and left ventricular function were 
the major end points of the study. Coronary venous catheteriza-
tion and retroperfusion were successfully performed in 15 pa-
tients. The target vessel was an unprotected left main artery in 2, 
left anterior descending artery in 10, left circumflex coronary 
artery in 1 and right coronary artery in 2 patients. A nonsup-
ported balloon inflation (mean 44 ± 13 s) was compared with a 
later retroperfusion-supported inflation (mean 145 ± 21 s). Right 
anterior oblique left ventriculograms, aortic blood pressure, pul-
monary artery pressure and thermodilution cardiac output were 
obtained before and during peak untreated and treated balloon 
inflations and on completion of angioplasty. 
All patients had either a baseline left ventricular ejection 
fraction <0.40 or >40% of contracting myocardium estimated to 
be at risk for severe ischemia during angioplasty. The cardiac 
(liters/min per m2) and stroke work (g·mlm2) indexes decreased 
from mean baseline values of 2.5 ± 0.52 and 52 ± 15 to 1.7 ± 0.47 
In recent years, the use of coronary angioplasty has had a 
major impact in the early management of unstable angina. 
Initially proposed as an alternative revascularization tech-
nique for patients with stable angina and single-vessel coro-
nary artery disease 0), its use and indications rapidly 
expanded to patients with multivessel coronary disease (2,3) 
and acute coronary syndromes (4,5), including acute myo-
cardial infarction (6,7). 
Within a wide spectrum of lesions for which coronary 
angioplasty is indicated, specific coronary lesions are known 
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and 27 ± 12 (mean ± SD), respectively, during nonsupported 
balloon inflations but decreased only to 2.1 ± 0.52 (p < 0.01 vs. 
nonsupported) and to 36 ± 14 (p = 0.01 vs. nonsupported), 
respectively, during retroperfusion-supported inflations. Ejection 
fraction (n = 8) decreased from a baseline value of 55 ± 13% to 
27 ± 7.3% during nonsupported inflations but only to 39 ± 10% 
during retroperfusion-supported inflations (p = 0.01 vs. nonsup-
ported). Regional wall motion (area change) in the ischemic 
(target) region was reduced from a baseline value of 49 ± 17% to 
11 ± 16% during nonsupported inflations but only to 27 ± 15% 
during retroperfusion-supported inflations (p < 0.01 vs. nonsup-
ported). 
All but two patients had a favorable hemodynamic response to 
retroperfusion. There were no serious adverse effects related to 
the procedures and no hospital deaths. It is concluded from this 
preliminary study that coronary venous retroperfusion appears to 
be safe, to provide hemodynamic support and to improve left 
ventricular function during angioplasty in patients with unstable 
angina and anatomy at high risk of a coronary event. 
(J Am Coli CardioI1991;18:283-92) 
to be associated with a higher incidence of abrupt coronary 
closure during angioplasty, including presence of a large 
thrombus, extreme lesion eccentricity and lengthy lesions 
(8). Patients are also considered to be high risk candidates 
for angioplasty on the basis of poor left ventricular function 
or large amounts of contracting myocardium supplied by the 
target vessel, or both (9). 
It has been well documented both in experimental (0) 
and in clinical studies (1) that severe regional myocardial 
dysfunction develops very rapidly after complete coronary 
occlusion, usually within 10 to 20 beats in the absence of 
significant collateral blood supply. Because many patients 
may not tolerate coronary occlusion and its consequences 
during balloon angioplasty, it may be necessary to support 
the ischemic myocardium and provide sufficient perfusion to 
vital organs during such an intervention. 
To improve the outcome of angioplasty for patients at 
high risk, a variety of techniques have been recently pro-
posed for supporting the circulation during the procedure 
(that is, "supported angioplasty" [12,13]). Such support can 
be accomplished by techniques that primarily provide direct 
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myocardial blood supply to the jeopardized region during 
transient coronary artery occlusion, or primarily provide 
hemodynamic support, or do both. 
Diastolic synchronized retroperJusion is in essence a 
myocardial circulatory assist technique. It is designed to 
provide autologous arterial blood to the ischemic myocar-
dium by way of the coronary veins. Retroperfusion has been 
extensively studied in animal models (14-19) and it has 
proved to be safe and effective in restoring myocardial 
function and reducing infarct size. It is now being tested in 
humans (20-24). In this report we present our initial expe-
rience with retroperfusion for support of angioplasty in high 
risk patients with unstable angina. 
Methods 
Study patients. Twenty patients were studied. Patients 
included in the study had rest angina refractory to maximal 
pharmacologic therapy in the coronary care unit, or angina 
with increasing frequency or severity of pain, or both, for ::52 
months before hospital admission. Rest angina was defined 
as chest pain at bed rest lasting >5 min accompanied by 
> 1 mm ST segment elevation or depression in ::::2 electro-
cardiographic (ECG) leads and initial creatine kinase MB 
isoenzyme values ::52 times the upper limits of normal. 
Patients were excluded from the study if there were con-
traindications to administration of an anticoagulant agent, or 
if they had a terminal illness, severe arterial hypertension 
(systolic blood pressure> 180 mm Hg or diastolic pressure 
> 115 mm Hg, or both), overt heart failure, severe valvular 
heart disease, akinesia or dyskinesia in the target region, 
cardiomyopathy, significant hypotension (systolic blood 
pressure <85 mm Hg) or shock. 
Clinical protocol. Patients were initially assessed in the 
coronary care unit for the presence of angina (Canadian 
Cardiovascular Society class), heart failure (Killip class), 
associated cardiac abnormalities, general clinical status and 
drugs. The patients were then transferred to the cardiac 
catheterization laboratory and diagnostic arteriography was 
performed using the femoral artery approach. A 5 to 10 mg 
dose of sublingual isosorbide dinitrate was then administered 
and angiography was repeated to rule out coronary spasm. 
The culprit lesion was identified and other lesions were 
assessed for possible angioplasty as well. Patients were then 
returned to the coronary care unit and drug administration 
including heparinization was continued at the discretion of 
their private physician. All patients were given aspirin and 
none received a thrombolytic agent. Blood counts and levels 
of creatine kinase and MB fraction, hematocrit, blood cre-
atinine, glucose, electrolytes, and a coagulation profile and 
chest X-ray film were obtained from all patients before 
catheterization. 
Retroperfusion-supported angioplasty was scheduled for 
the next day on the basis of high risk coronary anatomy 
(>40% of myocardium at risk) or low left ventricular ejection 
fraction, or both. Patients or immediate family members 
were asked to give written informed consent before the 
procedure, which was previously approved by the Institu-
tional Ethical Committee. Patients were then given meperi-
dine and diphenhydramine hydrochloride (both 50 mg intra-
muscularly). Angioplasty was performed with use of the 
(right) brachial artery approach. The ECG was monitored 
throughout the procedures. 
Retroperfusion technique. Detailed operation of the sys-
tem has been previously described (14-18,21,23). Briefly, 
the retroperfusion pump consists of an electronic console 
with an aligned disposable pumping cassette (Retroperfusion 
Systems). Arterial blood is shunted from the left femoral 
artery with an 8F single lumen withdrawal catheter with end 
and side holes. The withdrawal catheter is connected to the 
inlet of the pumping cassette, and the outlet of the cassette is 
connected to the infusion lumen of the retroperfusion cath-
eter, which is a radiopaque, 8.5F triple lumen balloon-tipped 
catheter, with the balloon located 10 mm from its distal end. 
At full inflation pressure, the balloon is oval shaped and 
10 mm in diameter. The balloon is inflated in diastole (second 
lumen) with a fixed volume of carbon dioxide, in synchroni-
zation with each pump stroke. Arterial blood is pumped in 
diastole by means of a piston activated by ECG triggering. In 
systole, the balloon deflates to allow for coronary venous 
blood drainage. The third lumen of the retroperfusion cath-
eter is used for monitoring coronary venous pressures. 
Catheterization procedures. The retroperfusion catheter 
was inserted by way of the right brachial vein or the right 
internal jugular vein. For retroperfusion of the myocardium 
supplied by the left anterior descending coronary artery, the 
catheter was positioned in the coronary sinus and advanced 
with the use of a 0.018 in. (0.46 cm) diameter guide wire as 
far as possible into the great cardiac vein, avoiding wedging 
of the catheter (position 3, described by Berland et al. [21]). 
For retroperfusion of the myocardium supplied by the left 
circumflex or right coronary artery, the catheter was placed 
more proximal to the coronary sinus to retroperfuse its 
terminal tributaries. Coronary venography with use of 
meglumine diatrizoate (Renografin-76) was performed in all 
patients to rule out large venous shunts and to verify 
appropriate compartmentalization of the coronary veins and 
drainage of the contrast material. At this stage, heparin, 
10,000 U, was given intravenously. 
A 7F pulmonary artery flotation catheter was inserted by 
way of the right internal jugular vein or right brachial vein for 
measurements of pulmonary artery pressures and thermodi-
lution cardiac output. Arterial blood pressure was monitored 
during the procedure through the side arm of the femoral 
artery introducer. The left ventricular stroke work index was 
determined with the following formula: Stroke work index 
(g·m/m2) = Thermodilution stroke volume index [Mean 
arterial pressure - Mean pulmonary capillary wedge pres-
sure] x 0.0136. 
Right anterior oblique ventriculograms with use of 
meglumine diatrizoate, 0.5 mllkg, were obtained with an 8F 
pigtail catheter before angioplasty, at peak retroperfusion-
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supported and nonsupported balloon inflations and on com-
pletion of angioplasty. End-diastolic and end-systolic vol-
umes were derived from ventriculograms with use of the 
area-length method described by Sandler and Dodge (25), 
and global left ventricular ejection fraction was calculated. 
Regional wall motion (area change) was derived from con-
trast ventriculograms using a fixed axis (26) and dividing the 
ventricle into four regions: anterior, apical, inferior and 
basal walls. Wall motion in the ischemic (target) zone was 
then contrasted with wall motion in the opposite wall (nonis-
chemic zone). 
To compare retroperfusion-supported and nonsupported 
inflations during angioplasty, the first balloon inflation 
served as a control (nonsupported) inflation and the second 
inflation was treated by retroperfusion. Retroperfusion was 
always initiated simultaneously with balloon inflation. The 
second angioplasty attempt was made after normalization of 
the ECG and cardiac output and never <5 min after the first 
angioplasty occlusion. No drugs were given during the 
procedures, with the exception of heparin, which was ad-
ministered to maintain an activated clotting time >400 s. 
Successful angiopiasty was defined as a residual diameter 
stenosis <50% by visual analysis of the angiogram, per-
formed by an observer who had no knowledge of patient 
data, in the absence of complications such as myocardial 
infarction or bypass surgery. 
After the patient was transferred to the coronary care 
unit, heparin was given intravenously at approximately 
1,000 U/h to maintain a partial thromboplastin time of 1.5 to 
2.5 times control values. Surgical backup was available for 
all patients. 
Statistical analysis. A statistical analysis of the following 
variables was performed: heart rate, systolic and diastolic 
blood pressure, cardiac index, stroke work index, ejection 
fraction and regional wall motionin the ischemic (target) and 
nonischemic zones. These variables were first analyzed with 
use of repeated measures of one-way analysis of variance for 
differences across the four time periods, that is, before 
angioplasty, during nonsupported and retroperfusion-
supported inflations and after angioplasty. If a significant 
difference (p < 0.05) was found across the four time periods, 
a paired t test was performed on the variables between the 
two time periods of interest, that is, nonsupported versus 
retroperfusion-supported balloon inflations, and a contrast 
between the average response at the pre- and postangio-
plasty periods to the average response during the nonsup-
ported and retroperfusion-supported periods was tested 
against the one-way analysis of variance mean squared 
error. Results are expressed as mean values ± SD. 
Results 
Excluded patients. Retroperfusion was successfully im-
plemented in 15 of the 20 patients (Table O. Ofthe other five 
patients, one had a large venous fistula connecting the 
anterior interventricular vein to the right atrium, and two 
patients with previous coronary bypass surgery (one with 
two previous operations) had a deformed coronary sinus so 
that appropriate placement of the retroperfusion catheter 
was not possible. In the fourth patient, the coronary sinus 
and great cardiac vein dimensions were very large; thus, the 
coronary venous system could not be compartmentalized 
after manual inflation of the balloon at the tip of the 
retroperfusion catheter with concomitant contrast venogra-
phy. In the fifth patient there was a mechanical failure of the 
retroperfusion pump. The data from these five patients were 
excluded from further analysis. 
Catheter placement. Among the 15 patients with success-
fully implemented retroperfusion, the retroperfusion cathe-
ter was introduced by way of the right brachial vein in 13 and 
by way of the right internal jugular vein in 2. Time for 
placement of the coronary sinus catheter ranged from 1 to 
15 min (median 3.5). 
Clinical and angiographic characteristics. Of the 15 pa-
tients, there were 3 with severe left main coronary artery 
stenosis who had previously undergone bypass surgery. Five 
additional patients had triple-vessel disease, four had dou-
ble-vessel disease and the remaining three had single-vessel 
left anterior descending coronary artery disease. Seven 
patients had had a previous Q wave myocardial infarction, 
and seven had a baseline left ventricular ejection fraction 
<40%. One patient with rest angina and signs of anterior 
wall ischemia on the ECG developed persistent ST segment 
elevation and prolonged chest pain while in the coronary 
care unit and was rushed to the catheterization laboratory 
for diagnostic catheterization and angioplasty. The left an-
terior descending coronary artery was not totally occluded. 
Blood sampling for creatine kinase collected before cathe-
terization showed a fivefold increase in enzyme release, 
confirming some degree of myocardial necrosis in this pa-
tient. 
An angiographic image suggestive of coronary artery 
thrombus in the culprit vessel was found in five patients at 
angioplasty. With use of the criteria of baseline left ventric-
ular ejection fraction <40% or a target vessel supplying 
>40% of contracting myocardium, or both, all 15 patients 
were considered high risk candidates for angioplasty. 
Coronary venous retroperfusion (Table 2, Fig. 1 to 4). 
Retroperfusion was applied at flow rates ranging from 125 to 
250 mllmin (median 171). The duration of untreated balloon 
inflations ranged from 25 to 75 s (mean 44 ± 13), whereas 
retroperfusion-supported inflations during angioplasty 
ranged from 90 to 240 s, with a mean retroperfusion pumping 
time of 145 ± 27 s. Peak coronary venous pressures mea-
sured 13 ± 4 mm Hg before angioplasty and 15 ± 3 mm Hg 
(systolic) during nonsupported balloon inflations and in-
creased to 42 ± 8 mm Hg (diastolic) during retroperfusion-
supported angioplasty (range 22 to 60 mm Hg, p < 0.001 vs. 
baseline or nonsupported inflations). Heart rate and blood 
pressure measured during the control period, at the end of 
the nonsupported and retroperfusion-supported· balloon in-
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Table 1. Clinical and Angiographic Data in 15 Patients 
Age (yrjl Previous Site of Supported Angiographic 
Patient Gender Clinical Status MI Coronary Stenosis > 50% Angioplasty Collateral flow 
45/M Angina, class IV No LADp subtotal; Diag I LAD No 
subtotal; LCx 50% 
2 49/M Angina, class IV No LADp 90%; RCA 50%; LAD No 
LCx 50% 
3 58/M Rest angina, AMI No LADp subtotal; LCx 50% LAD No 
4 411F Angina, class IV No LADp 90% LADlDiag 1* No 
5 57/M Rest angina No LADp 90%; PDA 50% LAD No 
6 70/M Angina, class IV Yes RCA 90%; LADp 100%; RCA RCA to LAD 
Marg 1 70% 
7 76/F Rest angina No RCA 90%; LADp 100% RCA RCA to LAD 
8 611M Angina, class IV Yes LADp 90%; Diag 1 90% LADlDiag 1* No 
9 63iM Angina, class III Yes LADp subtotal LAD/Diag 1* No 
10 371M Rest angina Yes LAD 90%; RCA 100%; LAD/Diag 1* No 
Diag 190% 
11 70/M Rest angina Yes LADp 90%; Diag 1 90%; LADlDiag 1* No 
RCA 100% 
12 62/M Angina, class III Yes RCA 90%; LCxp 90% LCx No 
13 66/M Angina, class IV No LM 90%; LAD graft 100%; LM No 
Marg 1 graft 100%; mid 
LCx 70% 
14 46/M Rest angina Yes LM 90%; LAD graft 100%; LM No 
LCx graft 100% 
15 59/M Angina, class III No LM 90%; RCA graft 90%; LIMA-LAD No 
mid RCA 90%; LIMA-
LAD 90% 
*Indicates occlusion of both arteries during balloon inflation. AMI = acute myocardial infarction; class III and class IV = Canadian Cardiovascular Society 
classes III and IV; Diag I = first diagonal branch of the left anterior descending artery; F = female; LAD = left anterior descending coronary artery; LADp = 
proximal left anterior descending coronary artery; LCx = left circumflex coronary artery; LCxp = proximal left circumflex coronary artery; LIMA-LAD = left 
internal mammary artery graft-left anterior descending artery anastomosis; LM = left main coronary artery; M = male; Marg 1 = first marginal branch of the 
proximal left circumflex coronary artery; PDA = posterior descending branch of the right coronary artery; RCA = right coronary artery. 
flations and on completion of angioplasty are summarized in 
Table 2. 
Hemodynamics. With use of repeated measures of one-
way analysis of variance, systolic blood pressure, cardiac 
index, stroke work index, left ventricular ejection fraction 
and ischemic zone wall motion showed a significant differ-
ence (p < 0.05) across the four time periods. In addition, a 
contrast between the average response at the pre- and 
postangioplasty periods to the average response during 
nonsupported and retroperfusion-supported inflations tested 
against the one-way analysis of variance mean squared error 
also showed a significant difference (p < 0.05) for these five 
variables. Coronary artery occlusion during nonsupported 
balloon inflations resulted in a significant reduction in sys-
tolic blood pressure, from a baseline of 116 ± 16 to 104 ± 
22 mm Hg, p < 0.05. Systolic pressure tended to increase 
during retroperfusion-supported inflations and to return to 
preangioplasty levels after the procedure. Thermodilution 
cardiac output and left ventricular stroke work decreased 
significantly during nonsupported inflations but decreased 
significantly less during retroperfusion-supported inflations 
(Fig. 1 and 2). 
Ventriculography. Patients with severe left main coro-
nary stenoses or baseline pulmonary capillary wedge pres-
Table 2. Hemodynamic Variables Before and During Nonsupported and Retroperfusion-Supported Angioplasty and After the Procedure 
Before 
During Angioplasty 
After 
Angioplasty Without SRP With SRP Angioplasty p Value' 
HR (beats/min) 68 ± 20 72 ± 20 72 ± 20 69 ± 15 0.30 
SBP (mm Hg) 116 ± 18 104 ± 22 108 ± 21 122 ± 15 0.0008 
DBP(mm Hg) 74 ± 10 70 ± 13 73 ± 12 75 ± 9 0.23 
'One-way analysis of variance, difference across the four time periods. DBP = diastolic blood pressure; HR = heart rate; SBP = systolic blood pressure; 
SRP = supported retroperfusion. 
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Figure 1. The cardiac index (CI, Llminlm2) in 14 patients before 
(PRE) and during nonsupported (-SRP) and retroperfusion-
supported (+ SRP) balloon inflations during coronary angioplasty, 
and on completion of the procedure (POST). Mean values at each 
time are indicated by the barred circles (p < 0.001 for differences 
across the four time periods; p = 0.0002 during nonsupported vs. 
retroperfusion-supported; p < 0.05 before or after vs. nonsupported 
or retroperfusion-supported balloon inflations). 
sure >22 mm Hg, or both, had only one ventriculogram 
before angioplasty. Thus, complete global and regional left 
ventricular function data derived from contrast ventriculo-
grams were available in eight patients. These data are 
Figure 2. The stroke work index (SWI, g·m1m2) in 14 patients (p < 
0.001 for differences across the four time periods; p = 0.001, -SRP 
vs. +SRP; p < 0.05, PRE or POST vs. -SRP or +SRP). Mean 
values at each time are indicated by the barred circles. Abbrevia-
tions as in Figure 1. 
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Figure 3. Global left ventricular (LV) ejection fraction in eight 
patients before and during unsupported and retroperfusion-
supported balloon inflations during angioplasty, and after the pro-
cedure (p < 0.001 for differences across the four time periods; 
p < 0.05 PRE or POST vs. -SRP or +SRP). Abbreviations as in 
Figure 1. 
presented in Figures 3 and 4, respectively. Global left 
ventricular ejection fraction decreased from a baseline of 55 
± 13% to 27 ± 7.3% during nonsupported inflations, but 
decreased to only 39 ± 10% during retroperfusion-supported 
inflations (p = 0.0016 vs. nonsupported inflations). After 
angioplasty, the ejection fraction was 58 ± 7.6%. Regional 
wall motion in the ischemic zone (Fig. 4) decreased signifi-
cantly less during retroperfusion-supported angioplasty, 
from a baseline of 49 ± 17% to 11 ± 15% during nonsup-
ported inflations compared with 27 ± 15% during retroper-
fusion-supported inflations (p < 0.01 vs. nonsupported infla-
Figure 4. Regional wall motion (RWM) in eight patients in the 
angioplasty target area (ischemic zone) and in the opposite wall 
(nonischemic zone) (p < 0.001 for differences across the four time 
periods in the ischemic zone; p = NS in the nonischemic zone; 
p < 0.01 PRE or POST vs. -SRP or +SRP). Abbreviations as in 
Figure 1. 
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tions). There was no significant change in wall motion in the 
nonischemic zone. Figure 5 shows left coronary arterio-
grams from Patient 4, and contrast ventriculograms from the 
same patient are shown in Figure 6. 
Complications. There were no serious complications dur-
ing the procedures. Two patients (Patients 7 and 13) had a 
local hematoma at the puncture site in the groin, requiring 
transfusions of 1 and 2 U of blood, respectively. Transient 
atrial arrhythmias occurred in four patients during coronary 
sinus catheterization, but spontaneously subsided a few 
minutes after catheter placement. There were no deaths 
related to the procedures or during the hospitalization pe-
riod. 
Angioplasty. Coronary angioplasty was performed in 1.4 
vessels/patient and was successful in 95% of vessels, includ-
Figure 5. Left coronary arteriograms in Patient 4. A, Before angio-
plasty there is a discrete, severe obstruction with an apparent filling 
defect in the proximal left anterior descending artery (arrow) just 
before the first diagonal branch. B, The inflated balloon during 
retroperfusion-supported angioplasty (the arrow points to the tip of 
the retroperfusion catheter). C, The proximal left anterior descend-
ing artery (arrow) after angioplasty. 
ing dilation of the left main coronary artery in three patients. 
Mean coronary stenosis diameter decreased from 91% to 
30%. None of the patients sustained a myocardial infarction 
Figure 6 (opposite page). Patient 4. Sequential contrast left ventric-
ulograms at end-diastole (left panels) and end-systole (right panels). 
A and B, Before angioplasty, there is hypokinesia of the anterior 
wall and apex, with a global ejection fraction of 37%. C and D, 
During nonsupported balloon inflations, there is akinesia of the 
anterior wall and apical dyskinesia (arrows) and hypercontraction in 
the inferior wall, with an ejection fraction of 26%. E and F, During 
retropetfusion-supported inflation, regional wall motion in the isch-
emic region improves and hypercontraction in the inferior wall 
decreases, with an ejection fraction of 32%. G and H, Immediately 
after angioplasty, there is only mild hypokinesia in the apical region 
and global ejection fraction increased to 55%. 
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or abrupt coronary closure after angioplasty and none re-
quired emergency bypass surgery. 
Discussion 
The high risk patient for coronary angioplasty. An in-
creasing number of patients with atherosclerotic coronary 
artery disease are considered to be high risk candidates for 
the procedure. In a relatively large proportion of such 
patients, temporary obstruction of the target vessel imposes 
an unacceptable risk for the procedure. Included in this 
category are patients with low baseline left ventricular 
ejection fraction, and patients with a target vessel supplying 
large portions of contracting myocardium, in whom hemo-
dynamic collapse or pulmonary edema, or both, are more 
likely to occur during angioplasty. Patients with unstable 
angina may have these conditions as well as an increased 
risk for developing abrupt coronary closure during or imme-
diately after angioplasty (4,5). During elective angioplasty, 
4% to 7% of the patients develop abrupt coronary artery 
closure (27,28). A significant proportion of these patients 
currently undergo emergency bypass surgery with an ap-
proximate 50% incidence of perioperative myocardial infarc-
tion and a reported mortality rate of approximately 7% 
(27,29). Therefore, it is important to develop rational thera-
peutic strategies for temporary circulatory assistance during 
high risk intracoronary arterial interventions. 
Supported angioplasty. The term assisted or supported 
angioplasty has been suggested to characterize the prophy-
lactic use of circulatory assist devices during high risk 
angioplasty (12). Obviously, some of these techniques can 
also be used in a standby fashion to be implemented in case 
complications occur. 
Several techniques have been proposed for support of 
high risk angiopiasty, including techniques that provide 
systemic circulatory or hemodynamic support and tech-
niques that primarily provide myocardial blood supply. 
Among the first group of techniques are the intraaortic 
balloon pump (30), hemopump (31), percutaneous femo-
rofemoral cardiopulmonary bypass (12) and percutaneous 
left atrial-aortic bypass pumping (32). These techniques do 
not provide direct myocardial perfusion. Among the myo-
cardial circulatory assist procedures there are three general 
categories: 1) techniques that provide active myocardial 
perfusion, such as coronary venous retroperfusion (21), 
anterograde diastolic phased coronary perfusion (33) or 
active anterograde catheter hemoperfusion (34); 2) tech-
niques that provide passive myocardial perfusion, such as 
the Stack autoperfusion catheter (35); and 3) techniques that 
provide perfusion with blood substitutes, such as perfluoro-
carbons (36). 
Clinical experience with the majority of these devices for 
support of high risk angioplasty is still relatively limited, and 
there are no controlled clinical studies comparing their 
relative efficacy under this condition. Clearly, there are 
advantages and disadvantages inherent to each of these 
techniques for specific clinical situations in patients at high 
risk for angioplasty. 
Retroperfusion for support of high risk angioplasty. Pre-
liminary studies (20,21) of retroperfusion for support of left 
anterior descending coronary artery angioplasty in patients 
with stable angina have demonstrated the feasibility of this 
technique, with minor complicatiQns in few patients. Ber-
land et al. (21) recently reported significant reduction in 
chest pain and ECG ST segment elevations during retroper-
fusion-supported balloon inflations during angioplasty, along 
with a moderate improvement in global left ventricular 
ejection fraction. However, the efficacy of retroperfusion in 
patients at high risk during angioplasty has not been clearly 
demonstrated. 
In this study we sought to investigate the effects of 
retroperfusion on hemodynamics as well as global and 
regional left ventricular function usi!1g contrast ventriculog-
raphy in a subset of patients at high risk for angioplasty. 
Hemodynamic improvement was observed in 13 of the 15 
patients studied. However, based on our limited observa-
tions we cannot be sure that retroperfusion alone will be 
sufficiently efficacious to prevent hemodynamic collapse in 
patients at high risk or to rescue patients who develop severe 
hypotension or cardiogenic shock after angioplasty. In our 
small series, only two patients developed severe hypoten-
sion during nonsupported angioplasty and in both patients 
blood pressure was well maintained during retroperfusion-
supported occlusions. 
Efficacy of retroperfusion. On the basis of previous ex-
perimental studies (14-17) and our own limited experience in 
the catheterization laboratory, several points appear to be 
critical for efficacy of retroperfusion. First, inflation of the 
balloon during diastolic retroperfusion must be fully occlu-
sive to compartmentalize the coronary venous system. In 
some patients, positioning of the catheter proximally in the 
coronary sinus or even in the midportion of the great cardiac 
vein will not be completely occlusive during balloon infla-
tion, allowing part of the retroperfusate to regurgitate into 
the right atrium and precluding diastolic coronary venous 
pressure augmentation during retroperfusion. Second, ap-
propriate positioning of the catheter tip also seems to be 
critical. For example, for retroperfusion of the left anterior 
descending coronary artery supply region, the tip of the 
retroperfusion catheter should be positioned deep into the 
great cardiac vein, in the vicinity of the anterior interven-
tricular vein (Fig. 5). Other factors may be important, such 
as more coaxial retroperfusion flows. A third crucial point is 
diastolic coronary venous pressure augmentation during 
retroperfusion. Previous experimental studies (37-41) have 
indicated that effective delivery of the retroperfusate is 
pressure-dependent. Diastolic pressure augmentation during 
synchronized retroperfusion depends on three major factors: 
1) effective compartmentalization of the coronary venous 
bed, 2) retroperfusion flow rate, and 3) coronary venous 
shunting. 
An important observation in human studies (21) com-
COSTANTINI ET AL. 291 JACC Vol. 18, No.1 
July 1991 :283-92 INITIAL EXPERIENCE WITH CORONARY VENOUS RETROPERFUSION 
pared with previous reports in animals is the lower diastolic 
pressure augmentation during retroperfusion in humans. As 
previously mentioned, several factors could be responsible 
for this difference, including the richer thebesian circulation 
in humans compared with animals. In our study, coronary 
venous pressures were higher than in a recent study (21), but 
were still much lower than the maximal safety limit of 
60 mm Hg peak pressure. This could be explained in part by 
the fact that we positioned the retroperfusion catheter 
deeper in the great cardiac vein for perfusion of the left 
ventricular anterior wall. Also, retroperfusion flow rates in 
our study were higher than those reported in the study of 
Berland et al. (21). Because retroperfusion efficacy seems to 
be directly related to the coronary venoarterial and coronary 
venous-left ventricular diastolic pressure gradients, as pre-
viously suggested in animal studies (14,37-41), it may be 
possible to enhance efficacy of retroperfusion by optimal 
catheter positioning and catheter operation mechanisms that 
can provide higher coronary venous pressures. 
Limitations of the study. One of the limitations of this 
study is that retroperfusion-supported inflations during an-
gioplasty were not randomized. Because the retroperfusion-
supported inflations were expected to be oflonger duration, 
we decided not to randomize balloon inflations for the 
following reasons: First, a more prolonged initial retroper-
fusion-supported balloon inflation could have caused myo-
cardial stunning (42) or ischemic preconditioning (43), pre-
cluding adequate assessment of ischemic changes during 
later inflations. Second, a more prolonged initial unsup-
ported inflation compared later against a retroperfusion-
supported inflation of the same duration would be associated 
with the same problems. To our knowledge, there is no 
evidence that a single coronary occlusion ::;60 s (only one 
patient had an initial unsupported occlusion > 1 min) is 
associated with significant collateral flow recruitment, isch-
emic preconditioning or myocardial stunning. 
Another potential problem is that repeated ventriculo-
grams over a relatively short period of time could have 
affected our hemodynamic and ventricular function mea-
surements adversely, although we waited for normalization 
of the ECGs and cardiac output and extended the time 
interval between supported and nonsupported balloon infla-
tions as much as possible. Also, contrast ventriculograms 
could not be obtained in all patients. 
State of the art retroperfusion equipment (with flow rate 
capability up to 250 mVmin) could be applied to only the last 
six patients in our study. It is possible that higher flow rates 
would have improved our results. Because the pumping time 
was restricted to a maximum of 4 min in this preliminary 
study, we cannot rule out the possibility of enhanced effec-
tiveness (or even loss of efficacy) if retroperfusion had been 
extended for prolonged periods of time. Clearly, further 
clinical evaluation with optimized flows and particularly 
ideal coronary venous pressures is needed before issues 
such as retroperfusion safety and efficacy can be definitely 
assessed. 
Although two of the three patients who had supported 
angioplasty of the right or left circumflex coronary artery 
had a positive response, more studies are needed to assess 
retroperfusion efficacy in these perfusion territories. Selec-
tive catheter positioning in the posterior ventricular or left 
marginal vein could be critical for perfusion of the left 
ventricular posterior and lateral walls, respectively, but 
additional factors such as better compartmentalization of the 
coronary venous bed and improved catheter stability may 
also be important. 
Conclusions. This preliminary study of retroperfusion-
supported angioplasty suggests that retroperfusion may be of 
value in supporting high risk intracoronary intervention 
procedures. Retroperfusion-supported angioplasty appears 
to be safe, and a moderate positive hemodynamic response, 
possibly secondary to improvements in myocardial perfu-
sion, was observed. Although this effect was seen in most of 
our patients, it is not possible to conclude from our data 
whether retroperfusion alone will be sufficient for hemody-
namic support during high risk angioplasty, particularly in 
patients with severe hypotension or shock. Other techniques 
for myocardial and hemodynamic support are currently 
being investigated; it is clear that many of them are not 
mutually exclusive, and further studies are needed to clarify 
not only which patients need support during intracoronary 
intervention, but also which techniques alone or in combi-
nation will be most appropriate for specific clinical situa-
tions. 
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